Skip to main content

Table 1 Patient demographics and characteristics at baseline (all enrolled population)

From: Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

  All patients (N = 42)
Demographics:  
 Age, years, mean ± SD 45.1 ± 12.7
 Gender, male: female, n 22: 20
 Body weight, kg, mean ± SD 76.7 ± 16.1
 Height in cm, mean ± SD 169.9 ± 9.0
 Race, n (%):  
  Caucasian 38 (90.5)
  Asian 1 (2.4)
  Hispanic 2 (4.8)
  Other 1 (2.4)
Treatment history, mean ± SD:  
 Age at diagnosis, years 24.8 ± 15.0
 Age at enzyme therapy initiation, years 35.6 ± 12.5
 Duration of enzyme therapy, years 9.5 ± 4.0
 Duration of current dose of enzyme therapy, years* 4.9 ± 2.8
 Enzyme therapy dose at switch, IU/kg/month 61.3 ± 35.7
Disease parameters, mean ± SD:  
 Liver volume in mL (n = 40) 1726 ± 459.6
 Liver volume in MN (n = 40) 0.91 ± 0.22
 Spleen volume in mL (n = 30) 484.7 ± 333.2
 Spleen volume in MN (n = 30) 3.13 ± 1.76
 Hemoglobin, g/dL (n = 41) 14.89 ± 1.49
 Platelet count, × 109/L (n = 41) 193.8 ± 92.06
  1. *Median (range) dose of enzyme therapy 54.7 (5.2–130.7) IU/kg/month; excludes splenectomized patients; MN, multiples of normal.